...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Genotype Phenotype Correlation of Genetic Polymorphism of PPAR Gamma Gene and Therapeutic Response to Pioglitazone in Type 2 Diabetes Mellitus- A Pilot Study
【24h】

Genotype Phenotype Correlation of Genetic Polymorphism of PPAR Gamma Gene and Therapeutic Response to Pioglitazone in Type 2 Diabetes Mellitus- A Pilot Study

机译：PPARγ基因多态性与2型糖尿病对吡格列酮治疗反应的基因型表型相关性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Pro12Ala polymorphism is a missense mutation at codon 12 in peroxisome proliferator-activated receptor ? gene (PPARG). This polymorphism is known to be associated with increased insulin sensitivity. Pioglitazone, a thiazolidinedione, is an anti-diabetic drug which acts as an agonist at PPAR ? receptor. Aim: To determine the association between Pro12Ala polymorphism of the PPARG and variation in therapeutic response to the PPAR? agonist, pioglitazone. Materials and Methods: The study was done as a hospital based pilot project in 30 patients with type 2 diabetes mellitus, on treatment with sulfonylurea or metformin but without adequate glycaemic control. They were started on pioglitazone as add on therapy for a period of 12 weeks. The participants were categorized as responders and non-responders based on the change in HbA1C level after 12 weeks. Pro12Ala polymorphism was analysed by polymerase chain reaction-restriction fragment length polymorphism. Statistical Analysis: Logistic regression analysis was done to evaluate the associations between age, baseline body weight, BMI, waist circumference, waist-hip ratio and Pro12Ala variants with the response to pioglitazone. The p-value< 0.05 was considered significant. Results: The frequency distributions of PPAR gamma genotypes were 80% for Pro/Pro and 20% for Pro/Ala in the study population. Among the study participants, 30% were non-responders and 70% responders to pioglitazone. A significantly higher frequency of the polymorphism was detected in the responders (p=0.005) compared to non-responders group. Conclusion: Our study suggests that there is a potential association between Pro12Ala polymorphism and glycaemic response to pioglitazone.
机译：简介：Pro12Ala多态性是过氧化物酶体增殖物激活受体中第12位密码子的错义突变。基因（PPARG）。已知该多态性与胰岛素敏感性增加有关。吡格列酮（一种噻唑烷二酮）是一种抗糖尿病药，可作为PPAR的激动剂？受体。目的：确定PPARG的Pro12Ala多态性与对PPAR的治疗反应差异之间的关联？激动剂吡格列酮。资料和方法：该研究以医院为基础的先导项目，针对30名2型糖尿病患者进行了磺酰脲类或二甲双胍的治疗，但没有足够的血糖控制。他们开始使用吡格列酮作为补充治疗，为期12周。根据12周后HbA1C水平的变化，将参与者分为反应者和非反应者。通过聚合酶链反应-限制性片段长度多态性分析Pro12Ala多态性。统计分析：进行逻辑回归分析以评估年龄，基线体重，BMI，腰围，腰臀比和Pro12Ala变体与吡格列酮的反应之间的关联。 p值<0.05被认为是显着的。结果：在研究人群中，PPARγ基因型的频率分布为Pro / Pro为80％，Pro / Ala为20％。在研究参与者中，对吡格列酮无反应者为30％，对吡格列酮的反应者为70％。与无反应者组相比，在反应者中检测到多态性的频率明显更高（p = 0.005）。结论：我们的研究表明Pro12Ala多态性与吡格列酮的血糖反应之间存在潜在的关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号